Northern Trust’s Theravance Biopharma TBPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.01M Buy
370,534
+40,607
+12% +$718K ﹤0.01% 2362
2025
Q4
$6.17M Sell
329,927
-11,379
-3% -$189K ﹤0.01% 2350
2025
Q3
$4.98M Sell
341,306
-10,919
-3% -$138K ﹤0.01% 2510
2025
Q2
$3.89M Buy
352,225
+2,808
+0.8% +$27.3K ﹤0.01% 2606
2025
Q1
$3.12M Sell
349,417
-40,563
-10% -$377K ﹤0.01% 2675
2024
Q4
$3.67M Buy
389,980
+6,198
+2% +$56.4K ﹤0.01% 2693
2024
Q3
$3.09M Sell
383,782
-81,185
-17% -$703K ﹤0.01% 2734
2024
Q2
$3.94M Sell
464,967
-23,785
-5% -$215K ﹤0.01% 2523
2024
Q1
$4.38M Sell
488,752
-33,184
-6% -$307K ﹤0.01% 2553
2023
Q4
$5.87M Sell
521,936
-34,459
-6% -$347K ﹤0.01% 2400
2023
Q3
$4.8M Sell
556,395
-61,113
-10% -$590K ﹤0.01% 2465
2023
Q2
$6.39M Sell
617,508
-30,571
-5% -$338K ﹤0.01% 2377
2023
Q1
$7.03M Buy
648,079
+11,674
+2% +$123K ﹤0.01% 2250
2022
Q4
$7.14M Buy
636,405
+38,102
+6% +$400K ﹤0.01% 2237
2022
Q3
$6.07M Buy
598,303
+3,069
+0.5% +$28.8K ﹤0.01% 2340
2022
Q2
$5.39M Buy
595,234
+6,181
+1% +$57K ﹤0.01% 2461
2022
Q1
$5.63M Sell
589,053
-25,308
-4% -$248K ﹤0.01% 2512
2021
Q4
$6.79M Buy
614,361
+11,723
+2% +$102K ﹤0.01% 2511
2021
Q3
$4.46M Buy
602,638
+41,705
+7% +$466K ﹤0.01% 2797
2021
Q2
$8.14M Buy
560,933
+41,703
+8% +$783K ﹤0.01% 2518
2021
Q1
$10.6M Sell
519,230
-19,462
-4% -$370K ﹤0.01% 2249
2020
Q4
$9.57M Sell
538,692
-65,010
-11% -$1.17M ﹤0.01% 2274
2020
Q3
$8.93M Sell
603,702
-29,626
-5% -$555K ﹤0.01% 2172
2020
Q2
$13.3M Buy
633,328
+11,158
+2% +$287K ﹤0.01% 1924
2020
Q1
$14.4M Buy
622,170
+50,594
+9% +$1.27M ﹤0.01% 1634
2019
Q4
$14.8M Sell
571,576
-6,094
-1% -$118K ﹤0.01% 1929
2019
Q3
$11.3M Buy
577,670
+24,041
+4% +$486K ﹤0.01% 2071
2019
Q2
$9.04M Buy
553,629
+3,547
+0.6% +$71.9K ﹤0.01% 2217
2019
Q1
$12.5M Sell
550,082
-714
-0.1% -$18.1K ﹤0.01% 2003
2018
Q4
$14.1M Buy
550,796
+4,274
+0.8% +$115K ﹤0.01% 1848
2018
Q3
$17.9M Buy
546,522
+11,238
+2% +$306K ﹤0.01% 1872
2018
Q2
$12.1M Buy
535,284
+18,733
+4% +$445K ﹤0.01% 2142
2018
Q1
$12.5M Buy
516,551
+4,509
+0.9% +$124K ﹤0.01% 2014
2017
Q4
$14.3M Sell
512,042
-14,253
-3% -$422K ﹤0.01% 1955
2017
Q3
$18M Sell
526,295
-3,754
-0.7% -$123K ﹤0.01% 1782
2017
Q2
$21.1M Buy
530,049
+30,611
+6% +$1.18M 0.01% 1630
2017
Q1
$18.4M Buy
499,438
+25,884
+5% +$827K 0.01% 1685
2016
Q4
$15.1M Buy
473,554
+48,560
+11% +$1.51M ﹤0.01% 1811
2016
Q3
$15.4M Buy
424,994
+274,760
+183% +$7.65M ﹤0.01% 1777
2016
Q2
$3.41M Sell
150,234
-163,078
-52% -$3.52M ﹤0.01% 2716
2016
Q1
$5.89M Buy
313,312
+8,898
+3% +$146K ﹤0.01% 2309
2015
Q4
$4.99M Buy
304,414
+42,347
+16% +$672K ﹤0.01% 2463
2015
Q3
$2.88M Sell
262,067
-3,956
-1% -$50.4K ﹤0.01% 2819
2015
Q2
$3.46M Buy
266,023
+5,297
+2% +$82.2K ﹤0.01% 2752
2015
Q1
$4.52M Buy
260,726
+12,884
+5% +$236K ﹤0.01% 2564
2014
Q4
$3.7M Sell
247,842
-17,694
-7% -$308K ﹤0.01% 2687
2014
Q3
$6.12M Buy
265,536
+152,158
+134% +$4.41M ﹤0.01% 2382
2014
Q2
$3.62M Buy
+113,378
New +$3.41M ﹤0.01% 2743

Other funds holding TBPH

Northern Trust's TBPH Position: Q1 2026 in Review

Northern Trust increased its Theravance Biopharma (TBPH) stake by 12% in Q1 2026, buying an estimated $718K and bringing the position to 370,534 shares worth $6.01M. The position accounts for ﹤0.01% of the portfolio, ranked #2362.

Northern Trust first reported a position in TBPH in Q2 2014 and has held it in 48 quarters since. The position peaked at $21.1M in Q2 2017. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • Northern Trust held 370,534 shares of Theravance Biopharma worth $6.01M as of Q1 2026.
  • Northern Trust bought 40,607 Theravance Biopharma shares in Q1 2026, an estimated $718K.
  • Theravance Biopharma made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #2362 holding.
  • Northern Trust first reported a position in Theravance Biopharma in Q2 2014 and has held it in 48 quarters since.
  • Northern Trust's Theravance Biopharma position peaked at $21.1M in Q2 2017.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.